Loading
Adding lenvatinib and pembrolizumab to chemoembolisation delayed progression in intermediate-stage liver cancer, the second trial to show that systemic therapy improves on embolisation alone, at the cost of more side effects.
Phase 3 placebo-controlled trial of 480 patients with unresectable, non-metastatic hepatocellular carcinoma suitable for chemoembolisation randomised to transarterial chemoembolisation with lenvatinib plus pembrolizumab or with dual placebo.
Median progression-free survival was 14.6 versus 10.0 months (hazard ratio 0.66), with an early trend in overall survival (hazard ratio 0.80, not significant) and grade 3 to 4 treatment-related adverse events of 71 versus 32 percent.
Lenvatinib-pembrolizumab with chemoembolisation is an emerging option for intermediate-stage disease, balanced against substantial toxicity.
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
Shares LEAP-012, Intermediate hepatocellular carcinoma (BCLC B).
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
Shares Intermediate hepatocellular carcinoma (BCLC B), Lenvatinib.
Shares Lenvatinib, The Lancet.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.